# Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

> **NCT03602586** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Malignant Ovarian Clear Cell Tumor
- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Epacadostat
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03602586
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-21
- **Primary completion:** 2021-02-01
- **Final completion:** 2024-03-27
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602586, "Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03602586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*